Glenmark Pharmaceuticals formulations business operates in over 95 countries including India. The company employs over 1700 medical reps across these markets; of these over 350 medical representatives and front line managers are employed in markets outside India.

In the semi-regulated markets spanning Asia, Africa, Latin America and Russia/CIS regions, the company has adopted a "Branded generics" model.

Glenmark's formulation business has invested in building a manufacturing footprint to cater to the demand. The current footprint includes:

	One WHO-GMP plant at Nasik to cater to semi-regulated markets including India. The plant handles several dosage forms including liquids, solids, semi-solids and dry powders.
	One ANVISA approved manufacturing plant in Brazil to cater to Latin American markets. This plant has capabilities in solids, liquids and semi-solids.

In India, the company markets about 100 molecules/combinations spanning a diverse set of therapy segments such as Dermatology, respiratory, gynaecology, pain management, diabetes, cardio-vascular, internal medicine etc. Over 50 of these molecules/combinations are also being marketed across the semi-regulated markets of Asia, Africa, Russia/CIS; several more products are under registration in these markets.